department

Clinical
Regulatory
Medical Affairs
Commercial
R&D / Discovery
Biostatistics / Data
Manufacturing / CMC
Market Access

therapeutic area

Oncology
Immunology
Neuroscience
Cardiovascular
Metabolic
Rare Disease
Infectious Disease

location & type

Remote Only
US Only
California
Massachusetts
Internships
Phase 3 Roles
All Jobs →

when

Latest
Archive

by source

All Sources
Sources Page

by activity

Most Active
Biggest Pipelines
Recently Active

hiring

Companies Hiring Now
Big Pharma Roles
All Companies →

Drugs & Pipeline

intelligence

Drugs
Patent Cliff

research

Publications
Topics

window

Next 90 Days
All (incl. Past)

by type

PDUFAs
Approvals
Earnings
Readouts

Sign In Subscribe

pharmadog

fetch the data · sniff the signal

Discover

Calendar
Drugs
Companies
News

Hubs

Topics
Jobs
Patent cliff
Publications

Tools

Compare
Search
Bookmarks

Trust

About
Sources
Contact

Legal

Privacy
Terms
Pricing

© 2026 pharmadog.xyz

made by humans and a good dog

home
jobs
news
cal
search

Metformin Hydrochloride · pharmadog

pharmadog
drugs
Metformin Hydrochloride

drug

patient view →

metformin hydrochloride ER

Marketedupdated 2mo ago

by Intellipharmaceutics Ltd

Approved

community read0 votes

indications

investigational

Type 2 Diabetes

all catalysts(2)

approval · 1

phase 2 completion · 1

News(0)

no news has mentioned this drug yet

brand

Metformin Hydrochloride

generic

metformin hydrochloride

indication

Type 2 Diabetes

phase

marketed

SITAGLIPTIN AND METFORMIN HYDROCHLORIDE (METFORMIN HYDROCHLORIDE) — FDA approval

metformin hydrochloride ER

phase 2 completion

National Institutes of Health — metformin hydrochloride ER (Phase II Trial Completion)

metformin hydrochloride ER

comments(0)

5-min edit window · permanent after that

sign in to leave a comment · permanent archive after 5 minutes

no comments yet — first sniff?

Data sources

openFDA · ClinicalTrials.gov

last refreshed 1h ago

Found something off?

🐶 something off?

Report a data issue

Tell Bork what looks wrong — wrong sponsor, stale phase, mislinked ticker, anything. We’ll triage and fix.

Patent cliff

source: FDA Orange Book

first barrier falls

Jul 31, 2026

24 days

Earliest of all listed patents + FDA exclusivities. Generic / biosimilar entry typically only becomes possible AFTER both patent and exclusivity barriers expire.

patents (13)

May 1, 2035formulationUS 9962336
Jan 21, 2029patentUS 8414921*PED2.5y
Jan 21, 2029patentUS 8414921*PED2.5y
Jul 21, 2028formulationUS 84149212.0y
Jul 21, 2028formulationUS 84149212.0y
May 24, 2027patentUS 7326708*PED321d
May 24, 2027patentUS 7326708*PED321d
Nov 24, 2026compositionUS 7326708140d
Nov 24, 2026compositionUS 7326708140d
Jul 31, 2026formulationUS 778562724d
Jul 31, 2026formulationUS 778562724d
Jul 31, 2026formulationUS 795994624d
Jul 31, 2026formulationUS 795994624d

🐶 often sniffed alongside

top 8

tagApproval48 co-mentions · 22 sources
drugSITAGLIPTIN AND METFORMIN HYDROCHLORIDE34 co-mentions · 26 sources
drugmetformin33 co-mentions · 26 sources
drugmetformin hydrochloride SR32 co-mentions · 26 sources
drugmetformin hydrochloride32 co-mentions · 26 sources
drugDAPAGLIFLOZIN AND SAXAGLIPTIN HYDROCHLORIDE22 co-mentions · 10 sources
drugDAPAGLIFLOZIN AND METFORMIN HYDROCHLORIDE22 co-mentions · 10 sources
drugDAPAGLIFLOZIN22 co-mentions · 10 sources

Trials studying metformin hydrochloride ER

phase1Study on Drug Interaction of Metformin Tablets and HRS-7535 Tablets in Healthy Humancompletedn=18
phase1A Study in Healthy People to Test Whether BI 764198 Influences the Amount of Metformin in the Bodycompletedn=14
phase1Modular Clinical Pharmacology Study to Evaluate the Drug-drug Interaction Potential and Relative Bioavailability of Saruparibactive not recruitingn=41
phase1A Study to Investigate the Effects of Multiple Doses of Rezatapopt on the Pharmacokinetics of Metformin, Rosuvastatin, Repaglinide, and Midazolam in Patients With Advanced Solid Tumors Harboring a TP53 Y220C Mutation.recruitingn=14
phase1Bioequivalence Study to Compare Empagliflozin / Metformin 25 mg/ 1000 mg Extended-Release Tablet Versus Synjardy XR Tablets 25mg/1000mg in Fast Conditioncompletedn=32
phase1A Study in Healthy Men to Test Whether Zongertinib Influences the Amount of 4 Other Medicines (Dabigatran, Rosuvastatin, Metformin, and Furosemide) in the Bloodcompletedn=32
phase1Bioequivalence Study to Compare Empagliflozin / Metformin 25 mg/ 1000 mg Extended-Release Tablet Versus Synjardy XR Tablets 25mg/1000mgcompletedn=40
phase4Efficacy of FDC Regimen of Dapagliflozin/Metformin Compared to Co-administered Dual Therapy on Glycemic Control, Satisfaction and Adherence in Chinese Patients With T2DMcompletedn=633

more trials →